• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Immix Biopharma Announces Dr. Comenzo Joins Advisory Board

    GLOBENEWSWIRE

    Nexcella Announces 100% Overall Response Rate (n=10) for CAR-T NXC-201

    GLOBENEWSWIRE

    Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201

    GLOBENEWSWIRE

    Nexcella Completes 3rd NXC-201 Engineering Batch at CAR-T Manufacturing Site

    GLOBENEWSWIRE

    Nexcella Announces Complete Response in NXC-201 Clinical Trial at IMS Meeting

    GLOBENEWSWIRE

    Nexcella Announces 72-Patient NXC-201 Clinical Data

    GLOBENEWSWIRE

    Nexcella Completes 2nd NXC-201 Engineering Batch

    CONTRACT PHARMA

    Nexcella Completes NXC-201 Engineering Batch at U.S. CAR-T Manufacturing Site

    GLOBENEWSWIRE

    Nexcella Announces NXC-201 AL Amyloidosis Data Accepted for Presentation

    GLOBENEWSWIRE

    Nexcella Announces NXC-201 Multiple Myeloma Data Accepted for Presentation

    GLOBENEWSWIRE

    Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial

    GLOBENEWSWIRE

    Nexcella Announces Commencement of NXC-201 Engineering Batches at Site

    GLOBENEWSWIRE

    Nexcella reports new data for CAR-T therapy in AL amyloidosis

    CLINICAL TRIALS ARENA

    Nexcella Announces Positive NXC-201 Clinical Results at ASGCT

    GLOBENEWSWIRE

    Nexcella Announces Late-Breaking NXC-201 Data Abstract Oral Presentation

    GLOBENEWSWIRE

    Nexcella, an Immix Biopharma Subsidiary, Announces 2023 NXC-201 Efficacy

    GLOBENEWSWIRE

    Nexcella Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy

    GLOBENEWSWIRE

    Nexcella, an Immix Subsidiary, Announces New Positive NXC-201 Clinical Data

    GLOBENEWSWIRE

    Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100%

    GLOBENEWSWIRE

    Nexcella to Discuss Recent Positive NXC-201 Clinical Data In AL Amyloidosis

    GLOBENEWSWIRE

    Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201

    GLOBENEWSWIRE

    Nexcella Enters into U.S. Agreement to Expand NXC-201 Phase 1b/2 Trial

    GLOBENEWSWIRE

    Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201

    GLOBENEWSWIRE

    Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.